阿托伐他汀对心肌梗死合并心衰患者行PCI后血清HsCRP和Copeptin的影响.pdf

摘 要 目的：探讨不同剂量阿托伐他汀对心肌梗死(AMI)合并心衰患 基端糖基化肽(Copeptin)的影响。 方法：将60例AMI合并心衰患者分为三组，行PCI前治疗组口 行PCI前ld、术后1d检测血清Copeptin。 结果：与治疗组合强化治疗组相比，术后一天和术后三天对照组 血清hs—CRP水平升高明显(PO．05)，而治疗组和强化治疗组血清 hs．CRP升高无差异；入院24小时，术前一天和术后一天，三组血清 治疗组和强化治疗组相比无差异。 结论：大剂量和中等剂量阿托伐他汀比常规剂量可明显降低AMI 低其心血管事件和冠状动脉支架术后再狭窄的几率并改善预后。 硕士研究生：陈晓(心血管内科) 指导教师：刘松(副主任医师) 关键词：心肌梗塞，急性；心力衰竭，充血性；经皮冠状动脉介入术： 阿托伐他汀 Abstract differentdosesof ordertodiscusstheeffectof atorvastatin 0b．iective：In the both infarctionandheartfailureinthe to patientmyocardial long．term the andrestenosisafter weobserveeffectofdifferent prognosis PCI，then of levelsC．reactiveand after dosesatorvastatinon of proteinCopeptin interventionfor infarctionwithheart coronary percutaneous myocardial that failure．Method：Thewhowerestudiedconsistedof60 population was totreatment and patientsrandomlyassigned group，controlgroup intensive was atorvastatin and therapygroup．whichgiven 20rag，40mg formeasurementofC．reactivewas 80mgperday．Bloodsamples protein the obtainedonfollowedl and3 after day，lday days procedure，and blood formeasurementwasobtainedonadmissionto samples